NIL-A is a neuroimmunophilin that was developed by Guilford and Amgen for Parkinson’s disease [1]. A second generation product, NIL-A succeeds an earlier immunophilin product called GPI-1046. Preclinical development of GPI-1046 itself appears to have been suspended [2]. Data from efficacy and pharmacokinetic studies with NIL-A were presented at the Acute Neuronal Injury: New Therapeutic Opportunities meeting in August of 1998, Las Vegas, USA. The compound apparently possesses 50% oral bioavailability, and approximately 25 fold greater efficacy compared with GPI 1046, as well as a superior half life and absorption profile. Continue Reading »

Their stories are amazing: Cardiac patients who recover rapidly after their own stem cells are implanted into their hearts; people with spinal cord injuries who have some feeling restored in their bodies.

“Miracle Cell” showcases some of the doctors and patients involved in experimental trials in regenerative medicine, which aims to harness the natural ability of the body to renew and heal itself. Continue Reading »